A research study published in British Medical Journal concluded that long-term gluten consumption is not associated with risk of coronary heart disease, but rather, a lack of gluten in the diet may affect cardiovascular risk. The study, co-authored by Celiac Disease Foundation Research Committee member, Benjamin Lebwohl, MD, and Celiac Disease Foundation Medical Advisory Board […]
The CDF Clinical Trial Finder will make it easier for patients with celiac disease and non-celiac gluten/wheat sensitivity to enroll in clinical trials, enabling patients to better engage with medical research and accelerate development of drugs and treatments.
A very commonly and hotly discussed topic in the celiac disease community is the determination of whom to screen for the disease and when. It is widely understood that celiac disease is under-diagnosed, especially since some individuals remain without symptoms for a long period of time. Blanket screening, however, seems inefficient; so where is the […]
A group of researchers recently published an article in the journal, Pediatrics, detailing the results of a nationwide study conducted in Sweden to examine the link between celiac disease and anorexia nervosa. Over the years, a relationship between the two diseases has been suggested, but analysis has been limited to case reports.
For decades, Celiac Disease Foundation (CDF) has advocated for more widespread diagnostic testing for symptomatic celiac disease patients and their first-degree family members (parent, child, sibling) to ease much of the needless suffering caused by the disease.
A research study published in the journal, Science, may have established a link between reovirus and celiac disease. Although reovirus is considered a common and often harmless virus, the study, co-authored by CDF Medical Advisory Board member, Stefano Guandalini, MD, and CDF Research Committee member, Sonia Kupfer, MD, determined that the reovirus, T1L, in some […]
23andMe has been approved by the FDA to offer direct-to-consumer genetic screening for a number of diseases, including celiac disease. Consumers are strongly cautioned to consult their physician
The March 19, 2017 Summit brought patients and consumer advocates together with guideline developers, methodologists, and other stakeholders in the clinical guideline enterprise for the purpose of constructive dialogue and initiation of durable relationships between them.
At the March 9 and 10, 2017 Genetic Alliance Conference, Celiac Disease Foundation worked to determine best strategies to help grow our iCureCeliac® patient registry, and to encourage patients and their family members to engage in the research process to influence the future of celiac disease research toward treatments and a cure.
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]